Liraglutide
GLP-1 receptor agonist
An earlier-generation GLP-1 receptor agonist widely referenced in comparative research.
Overview
Developed by Novo Nordisk as an acylated analog of human GLP-1 and one of the earlier long-acting GLP-1 receptor agonists. It received first FDA approval in 2010.
At a glance
What Liraglutide does
Liraglutide is a once-daily GLP-1 receptor agonist and the pharmacological ancestor of semaglutide. It is an acylated analog of native GLP-1 with a C16 palmitoyl fatty-acid chain that binds albumin and slows clearance, extending the half-life to about 13 hours — long enough for daily dosing but shorter than the weekly agonists. Its actions are the canonical GLP-1 profile: glucose-dependent enhancement of insulin secretion from beta cells, glucose-dependent suppression of glucagon, slowed gastric emptying, and activation of hypothalamic and brainstem appetite centers to reduce hunger and caloric intake. Because both insulin and glucagon effects are glucose-gated, it lowers blood sugar with minimal hypoglycemia when used alone.
In the LEAD type-2-diabetes program, liraglutide lowered HbA1c by roughly 1.0-1.5 percentage points with modest weight loss. At the higher 3.0 mg dose studied in the SCALE obesity trials, it produced mean weight reductions of about 8% over 56 weeks — meaningful but smaller than the newer weekly agents, which is part of why the field moved toward semaglutide and tirzepatide. Liraglutide also carries cardiovascular-outcome evidence: the LEADER trial showed a reduction in major adverse cardiovascular events in high-risk type 2 diabetics. It is well-characterized human-clinical, regulator-approved for both diabetes and weight management, and useful as the mechanistic and historical baseline against which the longer-acting and multi-receptor agonists are compared.
Effects reported in research
- Glucose-dependent enhancement of insulin secretion, lowering HbA1c ~1.0-1.5% in the LEAD diabetes trials (human clinical).
- Glucose-dependent glucagon suppression, reducing hepatic glucose output with low hypoglycemia risk (human clinical).
- Slowed gastric emptying, blunting post-meal glucose rises (human clinical).
- Reduced appetite and food intake via hypothalamic/brainstem GLP-1 receptors (human clinical).
- ~8% mean body-weight reduction at the 3.0 mg dose over 56 weeks in the SCALE obesity program (human clinical).
- Reduced major adverse cardiovascular events in high-risk type 2 diabetics in the LEADER trial (human clinical).
- Once-daily dosing profile (~13 h half-life), shorter-acting than the weekly agonists (human pharmacokinetic).
- Smaller weight effect than semaglutide/tirzepatide, serving as the class baseline (human clinical comparison).
Effects listed reflect findings reported in the research literature — many in animal or in-vitro models. Listing an effect is not a claim of efficacy or a therapeutic indication in humans.
Mechanism of action
Liraglutide is an analog of native GLP-1 sharing high sequence homology with the human hormone. It activates the GLP-1 receptor to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. A C16 palmitic fatty-acid chain attached via a glutamate linker promotes albumin binding and self-association, extending its duration relative to native GLP-1 and enabling once-daily dosing.
Mechanistic description reflects published research-literature understanding. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
What it's studied for
Research contexts in which Liraglutide appears in the literature. Listing a research area is not a claim of efficacy or a therapeutic indication.
Key characteristics
- Early-generation GLP-1 analog with high homology to native human GLP-1
- Uses a C16 palmitoyl fatty-acid side chain via a glutamate spacer for albumin binding
- Administered once daily by subcutaneous injection, a shorter dosing interval than weekly agents
- Marketed under distinct brand names for diabetes (Victoza) versus weight management (Saxenda)
- Studied in cardiovascular outcomes trials (e.g., the LEADER program)
- Its once-daily profile and shorter half-life distinguish it from later once-weekly analogs
Reported research dosing reference only
Educational reference, not dosing guidance. The figures below summarize amounts reported in published research and research-community protocols, provided for educational and research context only. They are not medical advice, not a recommendation, and not instructions for human use. Liraglutide is a research compound.
In the human clinical literature liraglutide is given once daily with a weekly stepwise escalation. These are reference figures describing published research/protocols, not dosing guidance for humans.
- Reported daily escalation: 0.6 mg -> 1.2 mg -> 1.8 mg -> 2.4 mg -> 3.0 mg once daily (weekly steps)
- Common maintenance references in the literature: 1.8-3.0 mg once daily
Short ~13-hour half-life is why it is dosed daily rather than weekly. Reference figures for research context only.
How it compares
Liraglutide is a once-daily GLP-1 agonist with a shorter half-life than the once-weekly semaglutide, reflecting its earlier-generation design.
Commonly studied alongside
Compounds frequently researched together with Liraglutide in the literature. Cross-referenced for research context — not a usage or combination recommendation.
Handling & Stability
Lyophilized peptides are stored cold, protected from light, and reconstituted only at the time of intended in-vitro work.
- Avoid repeated freeze-thaw cycles
- Verify supplier lot and Certificate of Analysis
- Follow institutional lab-safety protocols
Analytical & COA Concepts
Reputable research suppliers publish a third-party Certificate of Analysis per batch. Key analytical concepts referenced in COAs include:
Category Context
Liraglutide sits in the GLP-1 Family area of the PeptiDex library.
- Entry type: Research compound reference
- Browse the full library →
- Glossary of terms →
Where researchers source Liraglutide
For researchers studying Liraglutide, third-party suppliers such as Practically Natty Peptides offer research-grade material with third-party Certificates of Analysis and US-based shipping.
PeptiDex does not maintain a direct supplier listing for this compound. The link above goes to a third-party research-supplier directory.
Frequently asked questions
What is liraglutide and how does it differ from weekly GLP-1 agonists?
Liraglutide is a GLP-1 receptor agonist with a single C16 fatty-acid acylation that provides albumin binding and a roughly 13-hour half-life. Because that half-life is much shorter than semaglutide's, it is administered once daily rather than weekly in the literature. It is an earlier-generation reference GLP-1 agonist studied in glucose and body-weight models.
What does liraglutide's ~13-hour half-life imply for research design?
The ~13-hour half-life means once-daily administration and a much faster approach to steady state (within a few days) compared with weekly agonists. Washout is correspondingly quick — on the order of a few days. This daily-dosing profile is the main pharmacokinetic contrast researchers cite versus semaglutide and tirzepatide.
How is liraglutide dose-escalated in the literature?
Published protocols escalate daily, commonly starting at 0.6 mg and stepping up weekly through 1.2, 1.8, 2.4, and up to 3.0 mg once daily, depending on the endpoint studied. Escalation is used to improve gastrointestinal tolerability. These are reference figures for research context only, not human dosing guidance.
How does liraglutide relate to semaglutide structurally?
Both are acylated GLP-1 analogues from Novo Nordisk, but semaglutide has additional modifications (an Aib substitution and a longer C18 diacid linker) that greatly extend its half-life. Liraglutide is essentially the shorter-acting predecessor. Researchers use the pair to illustrate how acylation chemistry changes dosing frequency.
Is liraglutide an approved drug?
Yes — liraglutide is an approved once-daily injectable for glycemic and weight-management indications in humans. In a research catalog it is treated only as a reference research chemical and is not for human use.
How is research-grade liraglutide stored and reconstituted?
Lyophilized liraglutide is reconstituted with bacteriostatic water and kept refrigerated, protected from light and freeze-thaw. Expect a COA with HPLC purity (commonly greater than or equal to 98%) and mass-spec identity as the standard quality reference.
Answers are educational summaries of research-literature context and do not constitute medical advice. See the Research Library, COA guide, and Storage & Handling guide for more.